Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Neos Therapeutics

Nasdaq:NEOS
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NEOS
Nasdaq
$38M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Neos Therapeutics has significant price volatility in the past 3 months.
NEOS Share Price and Events
7 Day Returns
7.7%
NasdaqGM:NEOS
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-66.2%
NasdaqGM:NEOS
-2%
US Pharmaceuticals
-10%
US Market
NEOS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Neos Therapeutics (NEOS) 7.7% -42.3% -43.6% -66.2% -88.7% -
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • NEOS underperformed the Pharmaceuticals industry which returned -2% over the past year.
  • NEOS underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
NEOS
Industry
5yr Volatility vs Market

NEOS Value

 Is Neos Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Neos Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Neos Therapeutics.

NasdaqGM:NEOS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:NEOS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.65
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.646 (1 + (1- 21%) (127.08%))
1.198
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.198 * 5.44%)
8.25%

Discounted Cash Flow Calculation for NasdaqGM:NEOS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Neos Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:NEOS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.25%)
2020 0.95 Analyst x2 0.88
2021 10.25 Analyst x2 8.75
2022 21.35 Analyst x2 16.83
2023 37.80 Analyst x2 27.52
2024 46.85 Analyst x2 31.51
2025 53.53 Est @ 14.26% 33.26
2026 59.16 Est @ 10.51% 33.95
2027 63.82 Est @ 7.88% 33.83
2028 67.67 Est @ 6.04% 33.14
2029 70.88 Est @ 4.75% 32.07
Present value of next 10 years cash flows $251.00
NasdaqGM:NEOS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $70.88 × (1 + 1.74%) ÷ (8.25% – 1.74%)
$1,106.94
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,106.94 ÷ (1 + 8.25%)10
$500.80
NasdaqGM:NEOS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $251.00 + $500.80
$751.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $751.80 / 49.74
$15.11
NasdaqGM:NEOS Discount to Share Price
Calculation Result
Value per share (USD) From above. $15.11
Current discount Discount to share price of $0.77
= -1 x ($0.77 - $15.11) / $15.11
94.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Neos Therapeutics is available for.
Intrinsic value
>50%
Share price is $0.77 vs Future cash flow value of $15.11
Current Discount Checks
For Neos Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Neos Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Neos Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Neos Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Neos Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:NEOS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.34
NasdaqGM:NEOS Share Price ** NasdaqGM (2020-04-07) in USD $0.77
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Neos Therapeutics.

NasdaqGM:NEOS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:NEOS Share Price ÷ EPS (both in USD)

= 0.77 ÷ -0.34

-2.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neos Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Neos Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Neos Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:NEOS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
61.7%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Neos Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Neos Therapeutics's assets?
Raw Data
NasdaqGM:NEOS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.12
NasdaqGM:NEOS Share Price * NasdaqGM (2020-04-07) in USD $0.77
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:NEOS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:NEOS Share Price ÷ Book Value per Share (both in USD)

= 0.77 ÷ -0.12

-6.27x

* Primary Listing of Neos Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neos Therapeutics has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.
X
Value checks
We assess Neos Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Neos Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NEOS Future Performance

 How is Neos Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Neos Therapeutics expected to grow at an attractive rate?
  • Neos Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Neos Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Neos Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:NEOS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:NEOS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 61.7%
NasdaqGM:NEOS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 15.9%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:NEOS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:NEOS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 144 36 39 3
2023-12-31 122 29 31 3
2022-12-31 103 20 16 3
2021-12-31 87 13 3 4
2020-12-31 73 3 -8 4
2020-04-08
NasdaqGM:NEOS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 65 -11 -17
2019-09-30 63 -17 -23
2019-06-30 58 -28 -33
2019-03-31 54 -35 -45
2018-12-31 50 -41 -52
2018-09-30 44 -51 -56
2018-06-30 38 -52 -60
2018-03-31 32 -50 -63
2017-12-31 27 -53 -66
2017-09-30 21 -58 -70
2017-06-30 16 -61 -80
2017-03-31 12 -74 -88

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Neos Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Neos Therapeutics's revenue is expected to grow by 15.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:NEOS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Neos Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NEOS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.75 1.05 0.30 3.00
2023-12-31 0.60 0.90 0.21 3.00
2022-12-31 0.31 0.42 0.11 3.00
2021-12-31 0.04 0.11 -0.02 4.00
2020-12-31 -0.17 -0.12 -0.25 4.00
2020-04-08
NasdaqGM:NEOS Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.34
2019-09-30 -0.48
2019-06-30 -0.78
2019-03-31 -1.20
2018-12-31 -1.60
2018-09-30 -1.92
2018-06-30 -2.08
2018-03-31 -2.32
2017-12-31 -2.66
2017-09-30 -3.27
2017-06-30 -4.30
2017-03-31 -5.19

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Neos Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Neos Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Neos Therapeutics has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NEOS Past Performance

  How has Neos Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Neos Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Neos Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Neos Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Neos Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Neos Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Neos Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NEOS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 64.65 -16.90 41.36 8.58
2019-09-30 63.21 -22.75 44.29 9.16
2019-06-30 58.17 -33.40 48.29 9.64
2019-03-31 53.89 -44.84 52.58 10.01
2018-12-31 49.99 -51.68 58.05 8.51
2018-09-30 43.82 -55.99 60.47 7.89
2018-06-30 38.41 -59.55 63.02 7.61
2018-03-31 32.23 -62.99 62.78 8.92
2017-12-31 27.13 -65.77 60.69 8.96
2017-09-30 21.41 -70.49 58.48 10.78
2017-06-30 15.90 -80.05 62.07 11.90
2017-03-31 12.20 -87.94 66.45 11.95
2016-12-31 10.03 -82.75 61.92 12.21
2016-09-30 7.31 -74.06 54.72 11.33
2016-06-30 5.95 -57.86 37.94 10.99
2016-03-31 5.95 -38.21 20.80 9.35
2015-12-31 3.79 -33.17 12.75 11.69
2015-09-30 2.57 -29.74 8.22 11.37
2015-06-30 2.32 -26.20 6.24 11.56
2015-03-31 0.89 -25.71 5.39 12.64
2014-12-31 0.76 -24.15 5.27 10.57
2013-12-31 1.04 -22.01 5.62 9.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Neos Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Neos Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Neos Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Neos Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Neos Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NEOS Health

 How is Neos Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Neos Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Neos Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Neos Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Neos Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Neos Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Neos Therapeutics Company Filings, last reported 3 months ago.

NasdaqGM:NEOS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -6.13 43.77 24.89
2019-09-30 -3.03 43.43 25.28
2019-06-30 -1.61 43.11 30.25
2019-03-31 1.13 50.27 39.97
2018-12-31 7.85 49.92 46.48
2018-09-30 -26.64 59.91 16.56
2018-06-30 -18.64 59.92 28.04
2018-03-31 -4.52 59.92 37.22
2017-12-31 8.95 59.83 50.42
2017-09-30 14.70 65.92 66.49
2017-06-30 25.32 66.02 78.62
2017-03-31 12.61 66.01 54.23
2016-12-31 -1.55 63.52 39.78
2016-09-30 15.90 60.96 60.04
2016-06-30 40.70 60.32 80.12
2016-03-31 66.44 34.12 76.12
2015-12-31 78.37 34.24 90.76
2015-09-30 87.02 34.35 102.90
2015-06-30 15.18 34.46 25.63
2015-03-31 19.55 29.62 26.17
2014-12-31 13.16 24.77 16.34
2013-12-31 15.99 20.45 19.44
  • Neos Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Neos Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Neos Therapeutics has sufficient cash runway for 2.1 years based on current free cash flow.
  • Unable to confirm if Neos Therapeutics has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Neos Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Neos Therapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NEOS Dividends

 What is Neos Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Neos Therapeutics dividends.
If you bought $2,000 of Neos Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Neos Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Neos Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:NEOS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:NEOS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Neos Therapeutics has not reported any payouts.
  • Unable to verify if Neos Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Neos Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Neos Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Neos Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Neos Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Neos Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NEOS Management

 What is the CEO of Neos Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jerry McLaughlin
COMPENSATION $3,216,037
AGE 51
TENURE AS CEO 1.8 years
CEO Bio

Mr. Gerald W. McLaughlin, also known as Jerry, MBA has been the Chief Executive Officer of Neos Therapeutics, Inc. since joining on June 27, 2018 and its Director since June 2018. Mr. McLaughlin has been President of Neos Therapeutics, Inc. Mr. McLaughlin served as Chief Executive Officer and President of AgeneBio, Inc. since June 2014 until June 27, 2018. Mr. McLaughlin served as the Chief Commercial Officer and Senior Vice President at NuPathe, Inc., since October 2012 until 2014. He served as Vice President of Commercial Operations of NuPathe Inc. since September 2007. He has more than 17 years of specialty pharmaceutical industry experience in the U.S. and globally in new products planning, brand marketing and sales. Mr. McLaughlin was at Endo Pharmaceuticals from 2001 to 2007 and served in a variety of commercial leadership roles at Merck from 1990 to 2001. Mr. McLaughlin has launched twelve brands in a variety of therapeutic categories and has a strong background in strategic planning and commercial assessment. He worked the last six years in increasingly responsible positions at Endo Pharmaceuticals. In his last position as Senior Director of Strategic Marketing, Mr. McLaughlin led its portfolio planning efforts as well as commercial assessments and licensing and acquisition opportunities in Neurology, Supportive Care Oncology and Pain Management. He worked eleven years at Merck & Co. Inc., where he started as a sales representative and served as an Associate Director of Marketing in the Worldwide Human Health Division of Merck & Co. Inc., and was responsible for developing global business and product lifecycle plans for Merck products. He served as Regional Sales Director at Endo. He joined Endo in 2001 as Marketing Director and subsequently served as Group Marketing Director, Pain Products from 2002 to 2005. He served as Marketing Manager for Vioxx® and Market Research Analyst for Proscar® and Propecia®. He served as an Independent Director at Nemus Bioscience Inc. since October 2014 until January 18, 2018. Mr. McLaughlin has a B.A in Economics from Dickinson College and an MBA from Villanova University.

CEO Compensation
  • Insufficient data for Jerry to compare compensation growth.
  • Jerry's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Neos Therapeutics management team in years:

1.8
Average Tenure
51
Average Age
  • The average tenure for the Neos Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Jerry McLaughlin

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
51
TENURE
1.8 yrs

Rich Eisenstadt

TITLE
CFO, Treasurer & Corporate Secretary
COMPENSATION
$833K
AGE
61
TENURE
5.9 yrs

Margaret Cabano

TITLE
Vice President of Operations

John Limongelli

TITLE
Senior VP
AGE
49
TENURE
1.1 yrs

Joe Calarco

TITLE
Chief Compliance Officer
TENURE
2.2 yrs

Darren Heath

TITLE
Vice President of Sales
TENURE
1.4 yrs

Sarah Foster

TITLE
Vice President of Human Resources
TENURE
0.7 yrs

Russ McMahen

TITLE
Senior Vice President of Research & Development
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Neos Therapeutics board of directors in years:

4.7
Average Tenure
54
Average Age
  • The tenure for the Neos Therapeutics board of directors is about average.
Board of Directors

Al Heller

TITLE
Independent Chairman
COMPENSATION
$139K
AGE
65
TENURE
10.8 yrs

Jerry McLaughlin

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
51
TENURE
1.8 yrs

Greg Robitaille

TITLE
Independent Director
COMPENSATION
$128K
AGE
55
TENURE
10.8 yrs

John Schmid

TITLE
Independent Director
COMPENSATION
$129K
AGE
56
TENURE
4.8 yrs

Beth Hecht

TITLE
Independent Director
COMPENSATION
$120K
AGE
55
TENURE
4.6 yrs

Bryant Fong

TITLE
Independent Director
COMPENSATION
$123K
AGE
46
TENURE
10.8 yrs

Linda Szyper

TITLE
Independent Director
COMPENSATION
$163K
AGE
53
TENURE
2 yrs

Jim Robinson

TITLE
Independent Director
AGE
49
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Neos Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Neos Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NEOS News

Simply Wall St News

What Kind Of Investor Owns Most Of Neos Therapeutics, Inc. (NASDAQ:NEOS)?

Generally speaking, as a company grows, institutions will increase their ownership. … Neos Therapeutics is a smaller company with a market capitalization of US$163m, so it may still be flying under the radar of many institutional investors. … Check out our latest analysis for Neos Therapeutics

Simply Wall St -

Who Owns Most Of Neos Therapeutics Inc (NASDAQ:NEOS)?

I am going to take a deep dive into Neos Therapeutics Inc’s (NASDAQ:NEOS) most recent ownership structure, not a frequent subject of discussion among individual investors. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine NEOS's ownership structure in more detail.

Simply Wall St -

Has Neos Therapeutics Inc (NASDAQ:NEOS) Improved Earnings Growth In Recent Times?

Investors may find my commentary, albeit very high-level and brief, on Neos Therapeutics Inc (NASDAQ:NEOS) useful as an attempt to give more color around how Neos Therapeutics is currently performing. … View out our latest analysis for Neos Therapeutics? … Did NEOS beat its long-term earnings growth trend and its industry

Simply Wall St -

Should You Be Concerned About Neos Therapeutics Inc's (NASDAQ:NEOS) Investors?

In this analysis, my focus will be on developing a perspective on Neos Therapeutics Inc’s (NASDAQ:NEOS) latest ownership structure, a less discussed, but important factor. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: I suggest investors seek some degree of margin of safety due to high institutional ownership in NEOS, in particular due to the strong presence of active hedge fund investors.

Simply Wall St -

Are Earnings Prospects Improving For Loss-Making Neos Therapeutics Inc's (NASDAQ:NEOS)?

View our latest analysis for Neos Therapeutics Did NEOS's recent earnings growth beat the long-term trend and the industry? … This means that, Neos Therapeutics has historically performed better than recently, while it seems like earnings are now heading back towards to right direction again. … This means that, while Neos Therapeutics is currently running a loss, it may have gained from industry tailwinds, moving earnings towards to right direction.What does this mean?

Simply Wall St -

Is Neos Therapeutics Inc's (NASDAQ:NEOS) Balance Sheet A Threat To Its Future?

Does NEOS generate enough cash through operations? … With this growth in debt, NEOS currently has US$39.78M remaining in cash and short-term investments , ready to deploy into the business. … NasdaqGM:NEOS Historical Debt Mar 15th 18 Can NEOS service its debt comfortably?

Simply Wall St -

Breakeven On The Horizon For Neos Therapeutics Inc (NASDAQ:NEOS)

What rate will NEOS have to grow year-on-year in order to breakeven on this date? … For a more comprehensive look at NEOS, take a look at NEOS’s company page on Simply Wall St. … Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Neos Therapeutics’s board and the CEO’s back ground.

Simply Wall St -

Does Neos Therapeutics Inc's (NEOS) 29.3% Earnings Growth Make It An Outperformer?

Examining Neos Therapeutics Inc's (NASDAQ:NEOS) past track record of performance is an insightful exercise for investors. … NasdaqGM:NEOS Income Statement Dec 6th 17 We can further assess Neos Therapeutics's loss by looking at what has been happening in the industry as well as within the company. … I suggest you continue to research Neos Therapeutics to get a more holistic view of the stock by looking at: 1.

Simply Wall St -

Is Neos Therapeutics Inc's (NEOS) CEO Paid Enough To Stay Motivated?

Since 2013, Vipin Garg has been at the helm of Neos Therapeutics Inc (NASDAQ:NEOS) which has grown to a market capitalization of USD$285.02M. … In the past year, NEOS released negative earnings of -$80M , which is a further decline from prior year's loss of -$58M. … Usually I would look at market cap and earnings as a proxy for performance, however, NEOS's negative earnings reduces the usefulness of my formula.

Simply Wall St -

NEOS Company Info

Description

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.

Details
Name: Neos Therapeutics, Inc.
NEOS
Exchange: NasdaqGM
Founded:
$38,456,407
49,743,122
Website: http://www.neostx.com
Address: Neos Therapeutics, Inc.
2940 North Highway 360,
Suite 400,
Grand Prairie,
Texas, 75050,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM NEOS Common Stock Nasdaq Global Market US USD 23. Jul 2015
DB NTE Common Stock Deutsche Boerse AG DE EUR 23. Jul 2015
Number of employees
Current staff
Staff numbers
213
Neos Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 08:15
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/16
Last earnings filing: 2020/03/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.